“We very much look forward to the analysis of the primary endpoint of this important trial at six months, as this is the first prospective randomized trial of a sirolimus-coated balloon in AVF patients with angiographic follow-up. Furthermore, we have also measured fistula volume flow rates, which is another key index of failing or maintained fistula function.   I thank MedAlliance for initiating a trial in this difficult patient population” commented Principal Investigator (PI) Dr. Konstantinos Katsanos, MSc, MD, PhD, EBIR, Associate Professor of Interventional Radiology, Patras University Hospital , Patras, Greece.